EMCURE PHARMACEUTICALS
Back to Balance Sheet
|
EMCURE PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹812 Cr | ₹1,377 Cr | ₹905 Cr | ₹868 Cr | ₹883 Cr |
What is the latest Total Non-Current Liabilities ratio of EMCURE PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹812 Cr |
| Mar2024 | ₹1,377 Cr |
| Mar2023 | ₹905 Cr |
| Mar2022 | ₹868 Cr |
| Mar2021 | ₹883 Cr |
How is Total Non-Current Liabilities of EMCURE PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹812 Cr | -41.04 | |
| Mar2024 | ₹1,377 Cr | 52.24 | |
| Mar2023 | ₹905 Cr | 4.16 | |
| Mar2022 | ₹868 Cr | -1.64 | |
| Mar2021 | ₹883 Cr | - | |
Compare Total Non-Current Liabilities of peers of EMCURE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| EMCURE PHARMACEUTICALS | ₹35,699.6 Cr | 6.1% | 10.8% | 38.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹446,792.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,152.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,915.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹116,354.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,681.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | 6.1% |
10.8% |
38.8% |
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses